# | Title | Journal | Year | Citations |
---|
1 | Community-acquired pneumonia | Lancet, The | 2015 | 392 |
2 | Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study | Intensive Care Medicine | 2021 | 237 |
3 | New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study | American Journal of Respiratory and Critical Care Medicine | 2017 | 142 |
4 | A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia | Chest | 2017 | 136 |
5 | The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship | Intensive Care Medicine | 2017 | 103 |
6 | Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review | Respiratory Medicine | 2018 | 90 |
7 | Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort | Critical Care | 2021 | 69 |
8 | Early Bacterial Identification among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Clinical Trial | American Journal of Respiratory and Critical Care Medicine | 2021 | 65 |
9 | Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study | Critical Care | 2022 | 46 |
10 | Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations | Clinical Pharmacokinetics | 2016 | 42 |
11 | A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1 | Clinical Infectious Diseases | 2018 | 41 |
12 | A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study) | Antimicrobial Agents and Chemotherapy | 2018 | 30 |
13 | Low anti‐SARS‐CoV‐2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID‐19 patients | Journal of Internal Medicine | 2022 | 21 |
14 | Comparison of real‐time and droplet digital PCR to detect and quantify SARS‐CoV‐2 RNA in plasma | European Journal of Clinical Investigation | 2021 | 20 |
15 | A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens | Clinical Therapeutics | 2017 | 18 |
16 | Tracheostomy Timing and Outcome in Severe COVID-19: The WeanTrach Multicenter Study | Journal of Clinical Medicine | 2021 | 18 |
17 | Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe | Diagnostic Microbiology and Infectious Disease | 2018 | 16 |
18 | Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections | International Journal of Antimicrobial Agents | 2018 | 15 |
19 | Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program | Infectious Diseases and Therapy | 2021 | 15 |
20 | Preoperative staging of the mediastinum is an essential and multidisciplinary task | Respirology | 2020 | 14 |
21 | Nebulized antibiotics for ventilator-associated pneumonia: methodological framework for future multicenter randomized controlled trials | Current Opinion in Infectious Diseases | 2021 | 13 |
22 | Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe | Diagnostic Microbiology and Infectious Disease | 2019 | 11 |
23 | Confirmatory Mediastinoscopy after Negative Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Mediastinal Staging of Lung Cancer: Systematic Review and Meta-analysis | Annals of the American Thoracic Society | 2022 | 11 |
24 | Respiratory infections | European Respiratory Review | 2022 | 7 |
25 | Community-acquired pneumonia: Changing paradigms about mortality | Community Acquired Infection | 2014 | 5 |
26 | A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections | Journal of Medical Microbiology | 2020 | 3 |
27 | Pneumonia in 2016: towards better care | Lancet Respiratory Medicine,the | 2016 | 2 |
28 | The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens | Diagnostic Microbiology and Infectious Disease | 2018 | 2 |
29 | Importance of a registered and structured protocol when conducting systematic reviews: comments about nebulized antibiotics for ventilator-associated pneumonia | Critical Care | 2015 | 1 |
30 | Diagnostic yield of N3 hilar staging by endobronchial ultrasonography (EBUS) in lung cancer. | | 2018 | 0 |
31 | Benefits of a pilot program of supervised exercise training in Idiopathic Pulmonary Fibrosis | | 2018 | 0 |
32 | Community-acquired pneumonia: Changing paradigms about mortality | Community Acquired Infection | 0 | 0 |